TY  - JOUR
AU  - Brieger, Katharine K
AU  - Peterson, Siri
AU  - Lee, Alice W
AU  - Mukherjee, Bhramar
AU  - Bakulski, Kelly M
AU  - Alimujiang, Aliya
AU  - Anton-Culver, Hoda
AU  - Anglesio, Michael S
AU  - Bandera, Elisa V
AU  - Berchuck, Andrew
AU  - Bowtell, David D L
AU  - Chenevix-Trench, Georgia
AU  - Cho, Kathleen R
AU  - Cramer, Daniel W
AU  - DeFazio, Anna
AU  - Doherty, Jennifer A
AU  - Fortner, Renée T
AU  - Garsed, Dale W
AU  - Gayther, Simon A
AU  - Gentry-Maharaj, Aleksandra
AU  - Goode, Ellen L
AU  - Goodman, Marc T
AU  - Harris, Holly R
AU  - Høgdall, Estrid
AU  - Huntsman, David G
AU  - Shen, Hui
AU  - Jensen, Allan
AU  - Johnatty, Sharon E
AU  - Jordan, Susan J
AU  - Kjaer, Susanne K
AU  - Kupryjanczyk, Jolanta
AU  - Lambrechts, Diether
AU  - McLean, Karen
AU  - Menon, Usha
AU  - Modugno, Francesmary
AU  - Moysich, Kirsten
AU  - Ness, Roberta
AU  - Ramus, Susan J
AU  - Richardson, Jean
AU  - Risch, Harvey
AU  - Rossing, Mary Anne
AU  - Trabert, Britton
AU  - Wentzensen, Nicolas
AU  - Ziogas, Argyrios
AU  - Terry, Kathryn L
AU  - Wu, Anna H
AU  - Hanley, Gillian E
AU  - Pharoah, Paul
AU  - Webb, Penelope M
AU  - Pike, Malcolm C
AU  - Pearce, Celeste Leigh
TI  - Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
JO  - Gynecologic oncology
VL  - 153
IS  - 3
SN  - 0090-8258
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2020-01339
SP  - 702-709
PY  - 2020
N1  - 2020 Sep;158(3):702-709
AB  - Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:32641237
DO  - DOI:10.1016/j.ygyno.2020.06.481
UR  - https://inrepo02.dkfz.de/record/157048
ER  -